Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
J Aguilar-Serra, V Gimeno-Ballester, a Pastor-Clerigues, J Milara, C Trigo-Vicente & J Cortijo. (2022) Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer. Expert Review of Pharmacoeconomics & Outcomes Research 22:4, pages 637-646.
Read now
Read now
Fredrik O. L. Nilsson, Peter Gal, Ivan Houisse, Jasmina I. Ivanova & Sandra T. Asanin. (2021) The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden. Journal of Medical Economics 24:1, pages 447-457.
Read now
Read now
Marscha S Holleman, Harm van Tinteren, Harry JM Groen, Maiwenn J Al & Carin A Uyl-de Groot. (2019) First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. OncoTargets and Therapy 12, pages 1413-1421.
Read now
Read now
Ruxu You, Jinyu Liu, David Bin-Chia Wu, XinYu Qian, Boxiang Lyu, Yu Zhang & Nan Luo. (2019) Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China. Cancer Management and Research 11, pages 10239-10248.
Read now
Read now
Anna La Salvia, Emmanuele De Luca, Antonio Rossi & Massimo Di Maio. (2017) Can intercalating chemotherapy with epidermal growth factor receptor inhibitors delay development of treatment resistance in advanced non-small cell lung cancer?. Expert Opinion on Pharmacotherapy 18:18, pages 1899-1902.
Read now
Read now
Articles from other publishers (28)
Wei-Ting Chang, Hui-Wen Lin, Ting-Chia Chang, Sheng-Hsiang Lin & Yi-Heng Li. (2023) The association between tyrosine kinase inhibitors and fatal arrhythmia in patients with non-small cell lung cancer in Taiwan. Frontiers in Oncology 13.
Crossref
Crossref
Adam Pluzanski, Maciej Bryl, Izabela Chmielewska, Grzegorz Czyzewicz, Joanna Luboch-Kowal, Anna Wrona, Agnieszka Samborska & Maciej Krzakowski. (2023) Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study. Cancers 15:5, pages 1581.
Crossref
Crossref
Yuexiao Qi, Xiaojun Xia, Lihua Shao, Liyun Guo, Yumei Dong, Jinhui Tian, Lijun Xu, Ruijun Niu & Shihong Wei. (2022) An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer. Frontiers in Oncology 12.
Crossref
Crossref
Nicola Riccetti, Maria Blettner, Katherine Taylor, Beatrice Wehler, Bernhard Gohrbandt, Ursula Nestle, Robert Bals, Marcus Stockinger, Thomas Wehler, Susanne Singer & Martin Eichler. (2022) Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS. Journal of Cancer Research and Clinical Oncology 148:8, pages 1943-1953.
Crossref
Crossref
Hsiang-Sheng Wang, Chien-Ying Liu, Sheng-Chi Hsu, Shih-Chiang Huang, Tsai-Hsien Hung, Kwai-Fong Ng & Tse-Ching Chen. (2022) A Single-Institute Experience with C-ros Oncogene 1 Translocation in Non-Small Cell Lung Cancers in Taiwan. International Journal of Molecular Sciences 23:10, pages 5789.
Crossref
Crossref
Zhen Liu, Tian Tian, Binbin Wang, Demin Lu, Jian Ruan & Jianzhen Shan. (2022) Reducing Acneiform Rash Induced by EGFR Inhibitors With Honeysuckle Therapy: A Prospective, Randomized, Controlled Study. Frontiers in Pharmacology 13.
Crossref
Crossref
Bo Guo, Anthony D. Pomicter, Francis LiSudhir BhattChen ChenWen Li, Miao Qi, Chen Huang, Michael W. DeiningerMichael G. Kong & Hai-Lan Chen. (2021) Trident cold atmospheric plasma blocks three cancer survival pathways to overcome therapy resistance. Proceedings of the National Academy of Sciences 118:51.
Crossref
Crossref
Haifeng Qin, Fang Wang, Zhen Zeng, Suting Jia, Yuan Liu & Hongjun Gao. (2021) Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor–Mutated Advanced Non-Small-Cell Lung Cancer: Case Report. Frontiers in Pharmacology 12.
Crossref
Crossref
Yichen Shen & Haruko Noguchi. (2021) Impacts of anticancer drug parity laws on mortality rates. Social Science & Medicine 272, pages 113714.
Crossref
Crossref
Kumar Prabhash & Ullas Batra. (2021) Impact of epidermal growth factor receptor T790M testing in relapsed non-small cell lung cancer: A narrative review of the T790M reflex testing algorithm. Cancer Research, Statistics, and Treatment 4:4, pages 692.
Crossref
Crossref
Kazuhiko Nakagawa, Koichi Matsumura, Tayler Scory, Megan S Farris, Kelly A Larkin-Kaiser, Hironori Kikkawa, Jasmina I Ivanova & Keith D Wilner. (2021) Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population. Future Oncology 17:1, pages 103-115.
Crossref
Crossref
MeganS Farris, Kelly A Larkin-Kaiser, Tayler Scory, Devon Boyne, Keith D Wilner, Malaïka Pastel, Joseph C Cappelleri & Jasmina I Ivanova. (2020) Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival. Future Oncology 16:36, pages 3107-3116.
Crossref
Crossref
Carl Samuelsen & Ingolf Griebsch. (2020) Network meta-analyses for EGFR mutation-positive non-small-cell lung cancer: systematic review and overview of methods and shortcomings. Journal of Comparative Effectiveness Research 9:17, pages 1179-1194.
Crossref
Crossref
Zhimin Zhang, Xiaojuan Lian, Wei Xie, Jin Quan, Maojun Liao, Yan Wu, Zhen-Zhou Yang & Ge Wang. (2020) Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer. Scientific Reports 10:1.
Crossref
Crossref
Hend Nawara, Said Afify, Ghmkin Hassan, Maram Zahra, Marwa Atallah, Hager Mansour, Hagar Abu Quora, Md Alam, Amira Osman, Hiroki Kakuta, Hiroki Hamada, Akimasa Seno & Masaharu Seno. (2020) Paclitaxel and Sorafenib: The Effective Combination of Suppressing the Self-Renewal of Cancer Stem Cells. Cancers 12:6, pages 1360.
Crossref
Crossref
Marscha S. Holleman, Maiwenn J. Al, Remziye Zaim, Harry J. M. Groen & Carin A. Uyl-de Groot. (2019) Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. The European Journal of Health Economics 21:1, pages 153-164.
Crossref
Crossref
Hongwei Zhang, Jun Chen, Tingting Liu, Jun Dang & Guang Li. (2019) First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis. PLOS ONE 14:10, pages e0223530.
Crossref
Crossref
Jacob Franek, Joseph C Cappelleri, Kelly A Larkin-Kaiser, Keith D Wilner & Rickard Sandin. (2019)
Systematic review and network meta-analysis of first-line therapy for advanced
EGFR
-positive non-small-cell lung cancer
. Future Oncology 15:24, pages 2857-2871.
Crossref
Crossref
Kyung Hwa Choi, Jeong Yong Jeon, Young-Eun Lee, Seung Won Kim, Sang Yong Kim, Yeo Jin Yun & Ki Cheong Park. (2019) Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer. Translational Oncology 12:2, pages 381-388.
Crossref
Crossref
Yulin Li, Anita Appius, Thirupathi Pattipaka, Andrea Feyereislova, Adrian Cassidy & Apar Kishor Ganti. (2019) Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA. PLOS ONE 14:1, pages e0209709.
Crossref
Crossref
Yuichiro Ohe, Fumio Imamura, Naoyuki Nogami, Isamu Okamoto, Takayasu Kurata, Terufumi Kato, Shunichi Sugawara, Suresh S Ramalingam, Hirohiko Uchida, Rachel Hodge, Sarah L Vowler, Andrew Walding & Kazuhiko Nakagawa. (2019) Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Japanese Journal of Clinical Oncology 49:1, pages 29-36.
Crossref
Crossref
Byoung Chul Cho, Busayamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Virote Sriuranpong, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, Jong-Seok Lee, Helen Mann, Matilde Saggese, Thanyanan Reungwetwattana, Suresh S. Ramalingam & Yuichiro Ohe. (2019) Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. Journal of Thoracic Oncology 14:1, pages 99-106.
Crossref
Crossref
Francesca Mazzoni, Paolo Petreni, Marco Perna, Vieri Scotti, Stefano Bongiolatti, Lorenzo Livi, Francesco Di Costanzo & Luca Voltolini. (2018) Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences. Tumori Journal 104:6, pages NP5-NP9.
Crossref
Crossref
Jiunn-Liang Ko, Ching-Hsiung Lin, Heng-Chung Chen, Wei-Heng Hung, Peng-Ju Chien, Hui-Yi Chang & Bing-Yen Wang. (2018) Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environmental Toxicology 33:11, pages 1153-1159.
Crossref
Crossref
Nashrah Sharif Khan, Parvez Khan, Mohammad Fawad Ansari, Saurabha Srivastava, Gulam Mustafa Hasan, Mohammad Husain & Md. Imtaiyaz Hassan. (2018) Thienopyrimidine–Chalcone Hybrid Molecules Inhibit Fas-Activated Serine/Threonine Kinase: An Approach To Ameliorate Antiproliferation in Human Breast Cancer Cells. Molecular Pharmaceutics 15:9, pages 4173-4189.
Crossref
Crossref
Jeffrey W. Clark & Dan L. Longo. (2018) Recent progress in systemic treatment for lung cancer. Current Opinion in Pulmonary Medicine 24:4, pages 355-366.
Crossref
Crossref
Andreas Schalhorn. (2018) Osimertinib auch in der Erstlinie?. InFo Onkologie 21:2, pages 31-32.
Crossref
Crossref
Jean-Charles SoriaYuichiro OheJohan VansteenkisteThanyanan ReungwetwattanaBusyamas ChewaskulyongKi Hyeong LeeArunee DechaphunkulFumio ImamuraNaoyuki NogamiTakayasu KurataIsamu OkamotoCaicun ZhouByoung Chul ChoYing ChengEun Kyung ChoPei Jye VoonDavid PlanchardWu-Chou SuJhanelle E. GraySiow-Ming LeeRachel HodgeMarcelo MarottiYuri RukazenkovSuresh S. Ramalingam. (2018)
Osimertinib in Untreated
EGFR
-Mutated Advanced Non–Small-Cell Lung Cancer
. New England Journal of Medicine 378:2, pages 113-125.
Crossref
Crossref